VENT-02 Investigational brain-penetrant oral NLRP3 inhibitor in Phase 2 for Parkinson’s disease, targeting inflammatory activity within the central nervous system.
Visit productCosigns Received
Be the first Cosign
Put your name behind VENT-02.
Add it to your Products I use list and share why you use it.